Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

The Development of a Standardized Neighborhood Deprivation Index

Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Distorted Human Decision-Making as a Critical Aspect of Pandemic Planning and Preparedness.

Poland, C. M., Ratishvili, T., & Poland, G. A. (2022) · PubMed Central · Cited by 5

Trends in Confirmed COVID-19 Cases in the Korean Military Before and After the Emergence of the Omicron Variant

Shin, D. H., Jang, H., Lee, S., Choi, B. S., Kim, D., & Oh, H. S. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e260 · Cited by 5

Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity

Williams, D. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-13748-3 · Cited by 5

Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individualsPreprint

Peña-Hernández, M. A., Klein, J., Malik, A. A., Coppi, A. C., Kalinich, C. C., Vogels, C. B. F., Silva, J. D. S., Initiative, Y. S.-C.-2. G. S., Peaper, D. R., Landry, M.-L., et al. (2022) · medRxiv · doi:10.1101/2021.12.28.21268460 · Cited by 5

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models

Dudášová, J., Valenta, Z., & Sachs, J. R. (2024) · npj Vaccines · doi:10.1038/s41541-024-00937-6 · Cited by 4

Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status

Brummelman, J., Hernandez, S. S., de Rond, L., Bogaard, M., Molenaar, P., van Wijlen, E., Oomen, D., Beckers, L., Rots, N. Y., van Beek, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392477 · Cited by 4

Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study

Turpin, A., Semenzato, L., Vu, S. L., Jabagi, M.-J., Bouillon, K., Drouin, J., Bertrand, M., Kanagaratnam, L., Weill, A., Dray‐Spira, R., et al. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.05.007 · Cited by 4

A hybrid simulation approach for analyzing trends of infectious disease development, intervention measures and medical cost

Zhu, H., Jia, F., & Jia, F. (2025) · Journal of Simulation · doi:10.1080/17477778.2025.2488485 · Cited by 5

Lipid Nanoparticle-Mediated Systemic RNA Delivery to the Spleen: Strategies, Applications, and Challenges

Li, X., Wu, B., Lu, X., Yang, J., Zhu, Y., Yamagata, H. M., Tong, E. C., Mitchell, M. J., & Han, X. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00043 · Cited by 4

Population Density and Regional Differences Determine the Probability of COVID-19 Infection

Karaki, H. (2022) · Journal of Disaster Research · doi:10.20965/jdr.2022.p0061 · Cited by 4

Dynamic Analysis of a COVID-19 Vaccination Model with a Positive Feedback Mechanism and Time-Delay

Ai, X., Liu, X., Ding, Y., & Li, H. (2022) · Mathematics · doi:10.3390/math10091583 · Cited by 4

Assessing the Dynamic Outcomes of Containment Strategies against COVID-19 under Different Public Health Governance Structures: A Comparison between Pakistan and Bangladesh

Zhang, W., Huggins, T. J., Zheng, W., Liu, S., Du, Z., Zhu, H., Raza, A., & Tareq, A. H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159239 · Cited by 4

Predicting the COVID‐19 mortality among Iranian patients using tree‐based models: A cross‐sectional study

Aghakhani, A., Malak, J. S., Karimi, Z., Vosoughi, F., Zeraati, H., & Yekaninejad, M. S. (2023) · Health Science Reports · doi:10.1002/hsr2.1279 · Cited by 4

Humoral and cellular immune responses in fully vaccinated individuals with or without SARS‐CoV‐2 breakthrough infection: Results from the CoV‐ADAPT cohort

Hollstein, M. M., Dierks, S., Schön, M. P., Bergmann, A., Abratis, A., Eidizadeh, A., Kaltenbach, S., Schanz, J., Groß, U., Leha, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29122 · Cited by 4

Trends in the COVID-19 Pandemic in Italy during the Summers of 2020 (before Mass Vaccination), 2021 (after Primary Mass Vaccination) and 2022 (after Booster Mass Vaccination): A Real-World Nationwide Study Based on a Population of 58.85 Million People

Roncati, L., Bartolacelli, G., Galeazzi, C., & Caramaschi, S. (2023) · Pathogens · doi:10.3390/pathogens12121376 · Cited by 4

Vaccination strategies impact the probability of outbreak extinction: A case study of COVID-19 transmission

Jitsuk, N. C., Chadsuthi, S., & Modchang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28042 · Cited by 4

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants

Metzdorf, K., Jacobsen, H., 김연수, Alves, L. G. T., Kulkarni, U., Eschke, K., Chaudhry, M. Z., Hoffmann, M., Bertoglio, F., Ruschig, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383086 · Cited by 4

Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study

Kim, Y., Han, K., & Kim, J. H. (2024) · Ophthalmic Epidemiology · doi:10.1080/09286586.2024.2399345 · Cited by 5

Time-varying effects of COVID-19 vaccination on symptomatic and asymptomatic infections in a prospective university cohort in the USA

Robinson, L., Feting, A., Isozaki, I., Seyfert-Morgolis, V., Jay, M., Kim, E., & Cairns, C. B. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-084408 · Cited by 4

Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies

Pitiriga, V. C., Papamentzelopoulou, M., Nikoloudis, D., Saldari, C., Konstantinakou, K. E., Vasileiou, I. V., & Tsakris, A. (2025) · Pathogens · doi:10.3390/pathogens14050415 · Cited by 4

Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors

Ravera, F., Dameri, M., Lombardo, I., Stabile, M., Becherini, P., Fallani, N., Scarsi, C., Cigolini, B., Gentilcore, G., Domnich, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115838 · Cited by 4

Jabbing the economy back to life?

Gibson, J. K. (2022) · Applied Economics Letters · doi:10.1080/13504851.2022.2118216 · Cited by 4

Omicron: the highly mutational COVID-19 variant with immune escape

Khajotia, R. R. (2022) · Pan African Medical Journal · doi:10.11604/pamj.2022.41.84.33373 · Cited by 4

The response of the scientific community to a global crisis: a systematic review of COVID-19 research in 2020

Srivastava, P. R., Zhang, Z., Eachempati, P., Trivedi, S. K., & Jasimuddin, S. M. (2022) · British Journal of Healthcare Management · doi:10.12968/bjhc.2021.0068 · Cited by 4

The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis

Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Schweizer, M. L., Diekema, D. J., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., et al. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2021.261 · Cited by 5

Vaccine effectiveness against COVID‐19 among symptomatic persons aged ≥12 years with reported contact with COVID‐19 cases, February–September 2021

Chung, J. R., Kim, S. S., Belongia, E. A., McLean, H. Q., King, J. P., Nowalk, M. P., Zimmerman, R. K., Geffel, K. M., Martin, E. T., Monto, A. S., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12973 · Cited by 4

mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273

Dowell, A. C., Powell, A. A., Davis, C., Scott, S., Logan, N. A., Willett, B. J., Bruton, R. K., Ayodele, M., Jinks, E., Gunn, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882515 · Cited by 5

Incarcerated Older Adults in the Coronavirus Disease 2019 Era: A Call for Advancing Health and Human Dignity

Kheirbek, R., & Beamer, B. A. (2022) · Public Policy & Aging Report · doi:10.1093/ppar/prac021 · Cited by 4

Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS‐CoV‐2 Delta variant: A comprehensive review

Li, H. J., Arcalas, C., Song, J., Rahmati, M., Park, S., Koyanagi, A., Lee, S. W., Yon, D. K., Shin, J. I., & Smith, L. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2408 · Cited by 5

SARS-CoV-2 mRNA Dual Immunization Induces Innate Transcriptional Signatures, Establishes T-Cell Memory and Coordinates the Recall Response

Papadatou, I., Geropeppa, M., Verrou, K., Tzanoudaki, M., Lagousi, T., Liatsis, E., & Spoulou, V. I. (2023) · Vaccines · doi:10.3390/vaccines11010103 · Cited by 4

Dynamic behavior analysis of an $ SVIR $ epidemic model with two time delays associated with the COVID-19 booster vaccination time

Lv, Z., Liu, X., & Ding, Y. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023261 · Cited by 4

Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China

Guo, Y., Ye, W., Zhao, Z., Guo, X., Song, W., Su, Y., Zhao, B., Ou, J., Deng, Y., & Chen, T. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.02.002 · Cited by 4

Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo

Kodera, S., Takada, A., Rashed, E. A., & Hirata, A. (2023) · Vaccines · doi:10.3390/vaccines11030633 · Cited by 4

Serological Response to SARS-CoV-2 Vaccine in Hemodialyzed Patients and the Association with Later COVID-19 Positivity

Premužić, V., Stevanović, R., Vilibić‐Čavlek, T., Sirovica, M., Stalman, S., Bogdanić, M., Zilic, D., Nakić, D., Santini-Dušević, D., Vojković, M., et al. (2023) · Antibodies · doi:10.3390/antib12020037 · Cited by 4

Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease

Song, R., Yang, C., Li, Q., Wang, J., Chen, J., Sun, K., Lv, H., Yang, Y., Liang, J., Ye, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200198 · Cited by 4

Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India

Chaudhary, A., Madhavan, R., Babji, S., Raju, R., Syed, C., Kumar, A., Saravanan, P., Nikitha, O. S., Xavier, J. V. L., Chelladurai, J. S. D., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.059 · Cited by 4

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients

Dukes, C. W., Potez, M., Lancet, J. E., Kuter, B. J., Whiting, J., Mo, Q., Leav, B. A., Wang, H., Vanas, J., Cubitt, C. L., et al. (2023) · Vaccines · doi:10.3390/vaccines12010013 · Cited by 4

COVID-19 vaccine hesitancy and media channel use in Japan: could media campaigns be a possible solution?

Yoshioka, T. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100357 · Cited by 4

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years

Joseph, G., Klein, E., Lustig, Y., Weiss-Ottolenghi, Y., Asraf, K., Indenbaum, V., Amit, S., Kriger, O., Gilboa, M., Levy, Y., et al. (2022) · Vaccines · doi:10.3390/vaccines10111954 · Cited by 5

Modeling the impact of the Omicron infection wave in Germany

Maier, B. F., Burdinski, A., Wiedermann, M., Rose, A. H., Schlosser, F., der Heiden, M. A., Wichmann, O., Harder, T., & Brockmann, D. (2023) · Biology Methods and Protocols · doi:10.1093/biomethods/bpad005 · Cited by 4

The Mask-Wearing Bias In The Estimates Of Vaccine EfficacyPreprint

Matytsin, A. (2021) · medRxiv · doi:10.1101/2021.10.19.21265093 · Cited by 4

Effectiveness of mRNA COVID-19 Vaccination Against SARS-CoV-2 Infection and COVID-19 Disease in Sicily Over an Eight-Month PeriodPreprint

Amodio, E., Vella, G., Casuccio, A., & Vitale, F. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4001786 · Cited by 4

Vaccine Effectiveness Against COVID19-Infection and Onward Transmission by Variant of Concern and Time Since Vaccination, Belgian Contact Tracing, 2021Preprint

Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000559 · Cited by 4

Trends and Risk Factors of In-Hospital Mortality of Patients With COVID-19 in Germany: Results of a Large Nationwide Inpatient SamplePreprint

Hobohm, L., Sagoschen, I., Barco, S., Schmidtmann, I. M., Espinola–Klein, C., Konstantinides, S., Münzel, T. F., & Keller, K. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3979659 · Cited by 4

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021

(2022) · doi:10.1101/2022.03.29.22273086 · Cited by 4

Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort StudyPreprint

Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4180810 · Cited by 5

The efficacy and safety of an intranasal spray COVID-19 vaccine in a randomized double-blind placebo-controlled phase Ⅲ trial during Omicron periodPreprint

Xia, N., Zhu, F., Huang, S., Liu, X., Chen, Q., Zhuang, C., Han, J., Jaen, A. M., Do, T. H., Peter, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2407050/v1 · Cited by 4

Post-Pandemic Perspectives: Willingness, Risk Perception and Factors Influencing COVID-19 Booster Vaccine Uptake Among Thai Healthcare Workers and Vulnerable Populations

Kitro, A., Sirikul, W., Polpitakchai, C., Panumasvivat, J., Yamsiri, R., Tasena, P., Punyaphab, C., Rungsiyakull, C., Sapbamrer, R., Siviroj, P., et al. (2024) · Vaccines · doi:10.3390/vaccines12121381 · Cited by 4

Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States

Layton, J. B., Lloyd, P. C., Peetluk, L. S., Jiao, Y., Djibo, D. A., Gruber, J. F., Deng, J., Bui, C. L., Lo, A., Ogilvie, R. P., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320434 · Cited by 4

Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults

Lewnard, J. A., Malden, D. E., Hong, V. X., Skela, J., Feldstein, L. R., Saydah, S., Reyes, I., Hechter, R. C., Sy, L. S., Ackerson, B. K., et al. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004777 · Cited by 6

SHAP-integrated machine learning framework for interpretable survival modeling in a synthetic COVID-19 cohort

Rather, K. U. I. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100136 · Cited by 3

ATAGI Targeted Review 2021: the national COVID-19 vaccination program

Jayasinghe, S. H., Patel, C., Armstrong, L., Chiu, C., Macartney, K. K., Flanagan, K. L., Gibney, K. B., Giles, M., Crawford, N. W., Cheng, A., et al. (2023) · Communicable Diseases Intelligence · doi:10.33321/cdi.2023.47.20 · Cited by 3

Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January–December 2021

Lefferts, B., Bruden, D. J. T., Plumb, I. D., Hodges, E., Bates, E., January, G., & Bruce, M. G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.070 · Cited by 3

Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021

Mziou, E., Hchaichi, A., Letaief, H., Dhaouadi, S., Safer, M., Talmoudi, K., Mhadhbi, R., Elmili, N., Bouabid, L., Derouiche, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.02.028 · Cited by 3

Vaccination status and outcomes in critical COVID-19 patients

Costa, P. N., Pereira, J. O., Cañigral, A. H., Quintana, E. M., Sánchez-Nieto, J. M., Delis, P. B., Renedo-Villarroya, A., López-Gomez, L., Fernández, N. A., & Carrillo‐Alcaraz, A. (2024) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230116 · Cited by 4

Ecological comparison of six countries in two waves of COVID-19

Liu, M., Shi, L., Yang, M., Jiao, J., Yang, J., Ma, M., Xie, W., & Sun, G. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1277457 · Cited by 3

Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study

Ogilvie, R. P., Layton, J. B., Lloyd, P. C., Jiao, Y., Djibo, D. A., Wong, H., Gruber, J. F., Parambi, R. J., Deng, J., Miller, M. J., et al. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-04756-5 · Cited by 3

COVID-19 vaccine breakthrough infection among health care workers at MODHS hospitals in Saudi Arabia: A multicenter study

Elzahrany, Y. R., Alamry, A., Algeer, A., Alkhalifah, H. M., AlGhamdi, A., Alyateem, I. S., Alateah, S. M., Asghar, N., & Albarrak, A. M. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.04.021 · Cited by 3

A decision-making framework for supporting an equitable global vaccine distribution under humanitarian perspectives

Zhou, J., Cai, J., Pantelous, A. A., Li, Z., & Li, M. K. (2025) · European Journal of Operational Research · doi:10.1016/j.ejor.2025.05.007 · Cited by 3

Implications for general practitioner of evolution of incidence rates of COVID-19 breakthrough infections in vaccinated people as of December 2021 with the highest spike of infections of the entire pandemic

Turabián, J. L. (2022) · Archives of Community Medicine and Public Health · doi:10.17352/2455-5479.000168 · Cited by 3

Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design

Addala, S., Vissapragada, M., Aggunna, M., Mukala, N., Lanka, M., Gampa, S., Sodasani, M., Chintalapati, J., Kamidi, A., Veeranna, R. P., et al. (2022) · Vaccines · doi:10.3390/vaccines10060841 · Cited by 3

Patient-Reported Outcomes for Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough Cases

Vartanian, K. B., Fish, D., Gronowski, B., Kenton, N. R., & Robicsek, A. A. (2022) · Patient · doi:10.1007/s40271-022-00605-8 · Cited by 3

Concerns about and stimuli of COVID-19 vaccination hesitancy among diverse occupational groups in metropolitan areas of China: a cross-sectional study

Xie, Z., Tan, Y., Yan, Y., Gu, X., Chen, H., Huang, Q. E., Wang, Z., Gu, J., & Huang, J. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062032 · Cited by 3

Assessing parameter sensitivity in a university campus COVID-19 model with vaccinations

Childs, M. R., & Wong, T. E. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.04.002 · Cited by 3

Clinical characteristics and comorbidities associated with SARS-CoV-2 breakthrough infection in the University of California Healthcare Systems

Hogarth, M. A., John, D., Li, Y., Wang‐Rodriguez, J., Chakladar, J., Li, W. T., Mehta, S. R., Jain, S., & Ongkeko, W. M. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.04.019 · Cited by 4

An external validation of the QCOVID3 risk prediction algorithm for risk of hospitalisation and death from COVID-19: An observational, prospective cohort study of 1.66m vaccinated adults in Wales, UK

Lyons, J., Nafilyan, V., Akbari, A., Bedston, S., Harrison, E. M., Hayward, A. C., Hippisley‐Cox, J., Kee, F., Khunti, K. K., Rahman, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285979 · Cited by 3

Guidelines for Infection and Burnout Prevention in COVID-19 Healthcare Workers

Park, S. Y., Cheong, H. S., Kwon, K. T., Sohn, K. M., Heo, S. T., Lee, S., Chung, U., & Lee, S. H. (2023) · Korean Journal of Healthcare-Associated Infection Control and Prevention · doi:10.14192/kjicp.2023.28.1.50 · Cited by 3

Relative role of community transmission and campus contagion in driving the spread of SARS-CoV-2: Lessons from Princeton University

Park, S. W., Daskalaki, I., Izzo, R. M., Aranovich, I., Velthuis, A. J. W. T., Notterman, D. A., Metcalf, C. J. E., & Grenfell, B. T. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad201 · Cited by 3

Combining Aggregate and Individual-Level Data to Estimate Individual-Level Associations between Air Pollution and COVID-19 Mortality in the United States

Woodward, S. M., Mork, D., Wu, X., Hou, Z., Braun, D., & Dominici, F. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002178 · Cited by 3

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel

Weil, C., Bergroth, T., Eisenberg, A. L., Whiteside, Y. O., Caraco, Y., Tene, L., & Chodick, G. (2023) · Epidemiologia · doi:10.3390/epidemiologia4030031 · Cited by 3

Cell-based passive immunization for protection against SARS-CoV-2 infection

Sawula, E., Miersch, S., Jong, E. D., Li, C., Chou, F.-Y., Tang, J. K., Saberianfar, R., Harding, J. S., Sidhu, S. S., & Nagy, A. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03556-5 · Cited by 3

Daily fluctuations in COVID-19 infection rates under Tokyo’s epidemic prevention measures – new evidence from adaptive Fourier decomposition

Lu, G., Yang, Z., Qu, W., Qian, T., Liu, Z., He, W., Lin, Z., & Hon, C. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1245572 · Cited by 3

Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature

Mochizuki, S., Miura, J., Ucida, K., Kubota, R., Fujikawa, H., Takagi, S., Yoshida, N., Otake, S., Fujimori, C., Shinohara, A., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00695-9 · Cited by 3

Low antibody levels associated with significantly increased rate of SARS‐CoV‐2 infection in a highly vaccinated population from the US National Basketball Association

Tai, C. G.-L., Haviland, M. J., Kissler, S. M., Lucia, R. M., MERSON, M. H., Maragakis, L. L., Ho, D. D., Anderson, D. J., DiFiori, J. P., Grubaugh, N. D., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29505 · Cited by 3

Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination

Riccomi, A., Trombetta, C. M., Dorrucci, M., Placido, D. D., Sanarico, N., Farchi, F., Giuseppetti, R., Villano, U., Marcantonio, C., Marchi, S., et al. (2024) · Vaccines · doi:10.3390/vaccines12040425 · Cited by 3

BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study

Musa, S., Merdrignac, L., Skočibušić, S., Nedic, R., Cilović‐Lagarija, Š., & Kissling, E. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.047 · Cited by 3

COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort

Mallory, M. L., Munt, J. E., Narowski, T. M., Castillo, I. N., Cuadra, E., Pisanic, N., Fields, P., Powers, J. M., Dickson, A. M., Harris, R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi1379 · Cited by 5

Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study

Shoemaker, K., Soboleva, K., Branche, A. R., Shankaran, S., Theodore, D., Bari, M., Ezeh, V., Green, J. A., Kelly, E. J., Lan, D., et al. (2024) · Vaccines · doi:10.3390/vaccines12080883 · Cited by 3

Association of COVID-19 Vaccine Intake with Diagnosis, Hospitalization, and Oxygenation/Ventilation: A Longitudinal Analysis, 2021–2022, Japan

Odani, S., Honda, H., & Tabuchi, T. (2024) · Vaccines · doi:10.3390/vaccines12111264 · Cited by 3

One Year of COVID-19 mRNA Vaccines: Incredible Progress and Unfinished Business

Jhaveri, R. R. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.11.014 · Cited by 3

Breakthrough infections due to SARS-CoV-2 Wild type, the Delta variant and the Omicron variant in early fourth wave of epidemics in Myanmar

Pyar, K. P., Maung, N. L., Aung, Z. N. H., Aung, S. M., Win, T., Ya, K. Z., Kyaw, A. P., Kyaw, M. T., Aung, Z. P., Shan, M. A., et al. (2022) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v2-i2-10 · Cited by 4

Year 3 of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope

Poland, G. A., Issa, M., & Sundsted, K. K. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.10.022 · Cited by 3

Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population

Tschiderer, L., Seekircher, L., Richter, L., von Laer, D., Lass‐Flörl, C., Forer, L., Schönherr, S., Krammer, F., Embacher-Aichhorn, S., Tilg, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105380 · Cited by 3

Effect of patient COVID-19 vaccine hesitancy on hospital care team perceptions

Caspi, I., Freund, O., Pines, O., Elkana, O., Ablin, J. N., & Bornstein, G. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i4.821 · Cited by 4

Restrictions on Movement

Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0004 · Cited by 3

Effect of vaccination on SARS-CoV-2 reinfection risk: a case–control study in the Republic of Cyprus

Quattrocchi, A., Tsioutis, C., Demetriou, A., Kyprianou, T., Athanasiadou, M., Silvestros, V., Mamais, I., Demetriou, C. A., Theophanous, F., Soteriou, S., et al. (2022) · Public Health · doi:10.1016/j.puhe.2022.01.008 · Cited by 3

Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose

Berec, L., Levínský, R., Weiner, J., Šmíd, M., Neruda, R., Vidnerová, P., & Suchopárová, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-11250-4 · Cited by 3

Genomic Surveillance of SARS CoV2 in COVID-19 vaccinated healthcare workers in LebanonPreprint

Alkalamouni, H., Hassan, F. F. A., Hamdan, M. B., Page, A. J., Lott, M. C., Ghosn, N., Rady, A., Mahfouz, R. A., Araj, G. F., Dbaibo, G. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.06.494965 · Cited by 3

The Benefits and Costs of U.S. Employer COVID-19 Vaccine Mandates

Ferranna, M., Robinson, L., Cadarette, D., Eber, M., & Bloom, D. E. (2022) · National Bureau of Economic Research · doi:10.3386/w30339 · Cited by 4

COVID‐19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Preprint

Black, B. S., & Thaw, D. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155493 · Cited by 3

CD4+ and CD8+ T cell and antibody correlates of protection against Delta vaccine breakthrough infection: A nested case-control study within the PITCH studyPreprint

Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · medRxiv · doi:10.1101/2023.02.16.23285748 · Cited by 3

Special Issue: “Vaccination and Global Health”

Ma, S., Bi, Q., Liu, L., Thapa, R. J., Li, W., Liu, B., Xu, C., & Sun, C. (2024) · Vaccines · doi:10.3390/vaccines12111223 · Cited by 3

Effectiveness of COVID-19 vaccines against severe outcomes in cancer patients: Real-world evidence from self-controlled risk interval and retrospective cohort studies

Lee, H., Jeong, N., Park, M., Lim, E., Kim, J., Won, H., Kim, C.-J., Park, S. M., & Choi, N. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.03.015 · Cited by 3

COVID-19 Pandemic Fatigue: A Scoping Review of the Literature

Rashid, M. R. A., Suhaimi, A. S. A., Mohamad, S. N. S., Tajjudin, A. I. A., Roslan, N., Jaffar, A., Mohideen, F. B. S., Addnan, F. H., Baharom, N., & Ithnin, M. (2024) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.20.1.41 · Cited by 2

Costs of hospital admissions due to COVID-19 in the federal capital of Brazil: a study based on hospital admission authorizations

Pereira, A. C. E. D. S., Gallo, L. G., Oliveira, A. F. D. M., de Oliveira, M. R. F., & Peixoto, H. M. (2024) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2024.103744 · Cited by 2

Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients

Poolchanuan, P., Matsee, W., Dulsuk, A., Phunpang, R., Runcharoen, C., Boonprakob, T., Hemtong, O., Chowplijit, S., Chuapaknam, V., Siripoon, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-98627-3 · Cited by 2

The New Modern Medicine

Fuller, J. (2025) · doi:10.1093/9780190066178.001.0001 · Cited by 3

Including nonrandomized evidence in living systematic reviews: lessons learned from the COVID-NMA initiative

Bonnet, H., Higgins, J. P. T., Chaimani, A., Evrenoglou, T., Ghosn, L., Graña, C., Perrodeau, É., Yaacoub, S. G., Gabriel Rada, G., Bergman, H., et al. (2025) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2025.112071 · Cited by 3

2024–2025 COVID-19 mRNA Vaccine Effectiveness Against Severe Disease

Jayawardena, I., Dean, N. E., Witrick, B., Litwin, A. H., & Rennert, L. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag137 · Cited by 2

A Macro-Level Association of Vaccination Rate with the Number of Confirmed COVID-19 Cases in the United States and Japan

Noda, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127435 · Cited by 2

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort StudyPreprint

Tartof, S. Y., Slezak, J. M., Fischer, H. J., Hong, V. X., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909743 · Cited by 30

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant

Risk, M., Shen, C., Hayek, S. S., Holevinski, L., Schiopu, E., Freed, G. L., Akin, C., & Zhao, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac106 · Cited by 28

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative DesignPreprint

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111